Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00454051
First received: March 28, 2007
Last updated: August 2, 2011
Last verified: August 2011
  Purpose

The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with high dose of inhaled corticosteroid and long acting Beta-2 agonist.


Condition Intervention Phase
Asthma
Drug: Omalizumab
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment.

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change (%) From Baseline in FcεRI (High-affinity IgE Receptor) Expression on Blood Basophils and Dendritic Cells After 16 Weeks of Treatment With Omalizumab as Compared With Placebo [ Time Frame: Baseline and Week 16 ] [ Designated as safety issue: No ]
    Blood was drawn from participants at baseline and at Week 16. Basophils and dendritic cells expressing FcεRI were counted and the percentage was calculated. Fluorescence was used to label FcεRI so that they could be visualized. The greater the fluorescence intensity the greater FcεRI expression. The change from baseline is described by the difference (%) between the baseline value, before the first study drug administration, and the value observed at the end of study, expressed as a percent of the baseline value.

  • Change (%) From Baseline in Mean Fluorescence Intensity of FcεRI After 16 Weeks of Treatment With Omalizumab as Compared With Placebo [ Time Frame: Baseline and Week 16 ] [ Designated as safety issue: No ]
    Blood was drawn from participants at baseline and at week 16. Basophils and dendritic cells expressing FcεRI were counted and the percentage was calculated. Fluorescence was used to label FcεRI so that they could be visualized. The greater the fluorescence intensity the greater FcεRI expression. The change from baseline is described by the difference (%) between the baseline value, before the first study drug administration, and the value observed at the end of study, expressed as a percent of the baseline value.


Secondary Outcome Measures:
  • Change (%) From Baseline in Percent of Basophils and Dendritic Cells Expressing FcεRI After 4, 8, 12 and 16 Weeks of Treatment [ Time Frame: Baseline, Weeks 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
    Blood was drawn from a sub-group of participants at weeks 4, 8, 12, and 16. Basophils and dendritic cells expressing FcεRI were counted and the percentage was calculated. Fluorescence was used to label FcεRI so that they could be visualized. The change from baseline is described by the difference (%) between the baseline value, before the first study drug administration, and the value observed at the specified time point, expressed as a percent of the baseline value.

  • Change (%) From Baseline in the Mean Fluorescence Intensity of FcεRI After 4, 8, 12 and 16 Weeks of Treatment [ Time Frame: Baseline, Weeks 4, 8, 12, and 16 ] [ Designated as safety issue: No ]
    Blood was drawn from a sub-group of participants at weeks 4, 8, 12, and 16. Basophils and dendritic cells expressing FcεRI were counted and the percentage was calculated. Fluorescence was used to label FcεRI so that they could be visualized. The change from baseline is described by the difference (%) between the baseline value, before the first study drug administration, and the value observed at the specified time point, expressed as a percent of the baseline value.

  • Change From Baseline in the Number of Days With Asthma Symptoms Per Week [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the number of days with daytime asthma symptoms per week. This analysis compares the mean number of days per week with asthma symptoms during the 4-week screening period prior to randomization with the mean number of days per wek with asthma symptoms in the last 4 weeks of study treatment (Weeks 12 -16).

  • Change From Baseline in the Number of Puffs of Rescue Medication Per Week [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the daytime number of puffs of rescue Short-acting B2 agonist (SABA) used to treat asthma symptoms per week. This analysis compares the mean number of puffs of rescue medication per week during the 4 week screening period prior to randomization to the mean number of puffs per week during the last 4 weeks on study treatment (Weeks 12 - 16).

  • Change From Baseline in the Number of Nights With Awakenings Per Week [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the number of nights with awakenings due to asthma symptoms per week. For this analysis, the mean number of nights with awakenings per week during the 4 week screening period prior to randomization was compared with the mean number of nights with awakenings per week during the last 4 weeks of study treatment (Weeks 12 - 16).

  • Change From Baseline in the Number of Days With Impairment in Daily Activities Per Week [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Impairment was defined as days with physical activity considered as limited (or "not normal") according to patient's assessment and was recorded in a patient daily diary. For this analysis, the mean number of days with impairment per week during the 4 week screening period prior to randomization was compared with the mean number of days with impairment per week during the last 4 weeks on study treatment (Weeks 12 - 16).

  • Change From Baseline in the Number of Days With Absence From School or Work Due to Asthma Symptoms [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the number of days with absence from school or work due to asthma symptoms. For this analysis, the number of days with absence from school or work in the four weeks prior to randomization (screening period) were compared with the number of absence days during the last 4 weeks on study treatment (Weeks 12 - 16).

  • Change From Baseline in the Number of Days With Hospitalizations [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the number of days with hospitalizations during the study. For this analysis, the number of days with hospitalizations during the screening period (4 weeks prior to randomization) was compared with the number of days with hospitalizations during the last 4 weeks on study treatment (Weeks 12 - 16).

  • Change From Baseline in the Number of Unscheduled Clinic Visits [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Participants maintained a diary to record the number of unscheduled clinic visits during the study. For this analysis, the number of unscheduled visits during the 4 week screening period prior to randomization is compared with the number of unscheduled visits during the last 4 weeks on treatment (Weeks 12 - 16).

  • Change From Baseline in the Morning Daily Peak Expiratory Flow (PEF) [ Time Frame: Baseline (the 4 week screening period prior to randomization) and End of Study (Weeks 12 - 16) ] [ Designated as safety issue: No ]
    Peak Expiratory Flow (PEF) was measured every morning using a peak flow meter, and was recorded in the patient diary. For this analysis, the mean morning PEF during the 4-week screening period prior to randomizaton is compared with the mean morning PEF during the last 4 weeks of study treatment (Weeks 12 - 16).

  • Physician's Overall Assessment of Treatment Effectiveness [ Time Frame: After 16 weeks of treatment ] [ Designated as safety issue: No ]
    The Physician's overall assessment of treatment effectiveness was graded 1-5 as 1 = Excellent asthma control (complete control) 2 = Good asthma control (marked improvement) 3 = Moderate asthma control (discernible, but limited improvement) 4 = Poor asthma control (no appreciable change) 5 = Very poor asthma control (worsening)


Enrollment: 31
Study Start Date: December 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Omalizumab
Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
Drug: Omalizumab
Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
Placebo Comparator: Placebo
Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
Drug: placebo
Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.

Detailed Description:

Double blind placebo controlled study to assess the expression of IgE on blood basophils and dendritic cells in patients with uncontrolled, severe, persistent allergic asthma after a 16-week Omalizumab treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults aged >= 18 years.
  • Patients with severe persistent allergic asthma with the following characteristics:
  • FEV1 (Forced Expiratory Volume in One Second) <80% of predicted.
  • Frequent daily symptoms (>=4 days/week on average) or nocturnal awakening (>=1/week on average).
  • Multiple severe asthma exacerbations: either >=2 severe asthma exacerbations having required an unscheduled medical intervention with systemic corticosteroid in the past year, or hospitalization (including emergency room treatment) for an asthma exacerbation in the past year.
  • Despite a high dose inhaled corticosteroid >1000 mg beclomethasone dipropionate or equivalent and a inhaled long-acting B2-agonist.
  • With an allergy to a perennial allergen demonstrated with convincing criteria, i.e. positive prick skin test or in vitro reactivity to a perennial aeroallergen (RAST).
  • Total serum IgE level >= 30 to <=700 IU/ml and suitable serum total IgE level and weight according to Xolair dosing tablets.

Exclusion Criteria:

  • Age < 18 years.
  • Smoking history > 20 pack years.
  • Patients who have had an asthma exacerbation during the 4 weeks prior to randomization
  • History of food or drug related severe anaphylactoid or anaphylactic reaction
  • Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis).
  • Patients with active cancer, suspicion of cancer or any history of cancer.
  • Pregnant women.
  • Known hypersensitivity to omalizumab or to one of its components.
  • Patients already treated with omalizumab (indeed a previous treatment with omalizumab could have modified the FceRI expression).
  • Patients who had participated in a clinical trial in the past 3 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00454051

Locations
France
Novartis Investigator site
Rueil-Malmaison, France
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: External Affairs, Novartis
ClinicalTrials.gov Identifier: NCT00454051     History of Changes
Other Study ID Numbers: CIGE025AFR02
Study First Received: March 28, 2007
Results First Received: December 3, 2010
Last Updated: August 2, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Novartis:
Asthma, anti-immunoglobulin E, omalizumab, IgE receptors

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on July 26, 2014